

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**FOURTH QUARTER**  
**2006**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	4Q '06 vs. 4Q '05					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	11%	865	18%	319	7%	546
FOSAMAX	-	789	7%	517	-11%	272
SINGULAIR	17%	960	21%	691	9%	268
ZOCOR	-65%	379	-80%	161	-15%	218
Other Reported Products:						
AGGRASTAT	-10%	19	N/A	-	-10%	19
ARCOXIA	33%	74	N/A	-	33%	74
CANCIDAS	-16%	133	-46%	49	25%	84
COSOPT / TRUSOPT	7%	179	9%	80	6%	100
CRIXIVAN / STOCRIN	-2%	89	-41%	7	4%	82
EMEND	28%	36	10%	25	*	10
INVANZ	49%	41	51%	24	46%	16
MAXALT	18%	111	23%	75	9%	36
PRIMAXIN	-5%	181	1%	58	-8%	124
PROPECIA	19%	103	3%	37	31%	66
PROSCAR	-38%	120	-75%	25	2%	95
TIMOPTIC / TIMOPTIC XE	-5%	33	-5%	2	-5%	31
VASOTEC / VASERETIC	-10%	136	N/A	-	-10%	136
HEPATITIS VACCINES	39%	67	50%	57	-	11
VIRAL VACCINES <sup>(1)</sup>	*	482	*	453	*	30
OTHER VACCINES	20%	134	26%	118	-11%	16

\* 100% or over  
N/A - Not Applicable

<sup>(1)</sup> Includes new vaccine sales: Gardasil \$155m, ProQuad \$89m, RotaTeq \$69m, and Zostavax \$27m.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	4Q '06	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES <sup>(2)</sup></b>	<u>\$ 6,044</u>	<u>5%</u>	<u>6</u>	<u>-2</u>	<u>1</u>
U.S. (\$ MM)	3,750	8%	9	-1	N/A
Foreign (\$ MM)	2,294	-	1	-4	3

<sup>(2)</sup> Includes: Januvia \$42m, Zolinza \$1m.

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**DECEMBER YEAR-TO-DATE**  
**2006**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	DECEMBER YTD `06 vs. DECEMBER YTD `05					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	4%	3,163	10%	1,140	1%	2,023
FOSAMAX	-2%	3,134	8%	1,983	-15%	1,152
SINGULAIR	20%	3,579	26%	2,578	7%	1,001
ZOCOR	-36%	2,803	-40%	1,887	-26%	915
Other Reported Products:						
AGGRASTAT	-2%	86	N/A	-	-2%	86
ARCOXIA	22%	265	N/A	-	22%	265
CANCIDAS	-7%	530	-30%	219	21%	311
COSOPT / TRUSOPT	13%	697	23%	306	6%	391
CRIXIVAN / STOCRIN	-6%	327	-37%	25	-2%	302
EMEND	50%	131	34%	99	*	32
INVANZ	48%	139	43%	83	57%	56
MAXALT	17%	406	19%	267	12%	139
PRIMAXIN	-5%	705	-	212	-6%	493
PROPECIA	21%	352	13%	145	27%	207
PROSCAR	-17%	618	-34%	244	1%	375
TIMOPTIC / TIMOPTIC XE	-8%	127	-14%	9	-8%	118
VASOTEC / VASERETIC	-12%	547	N/A	-	-12%	547
HEPATITIS VACCINES	28%	248	34%	202	5%	47
VIRAL VACCINES <sup>(1)</sup>	*	1,257	*	1,161	57%	96
OTHER VACCINES	14%	354	22%	294	-14%	60

\* 100% or over  
N/A - Not Applicable

<sup>(1)</sup> Includes new vaccine sales: Gardasil \$235m, ProQuad \$235m, RotaTeq \$163m, and Zostavax \$39m.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	FY '06	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES <sup>(2)</sup></b>	<u>\$ 22,636</u>	<u>3%</u>	<u>3</u>	<u>-</u>	<u>-</u>
U.S. (\$ MM)	13,777	8%	6	2	N/A
Foreign (\$ MM)	8,859	-4%	-1	-3	-1

<sup>(2)</sup> Includes: Januvia \$43m, Zolinza \$1m.

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**FOURTH QUARTER**  
**2006**

**OTHER (INCOME) EXPENSE, NET (millions of dollars)**

	4Q `06	4Q `05	YTD 2006	YTD 2005
INTEREST INCOME	\$ (199.7)	\$ (166.0)	\$ (764.3)	\$ (480.9)
INTEREST EXPENSE	97.2	108.2	375.1	385.5
EXCHANGE (LOSSES) GAINS	(20.5)	0.4	(25.0)	(16.1)
MINORITY INTERESTS	29.9	30.2	120.5	121.8
Other, net	16.0	(99.1)	(89.0)	(120.5)
<b>TOTAL</b>	<b>\$ (77.1)</b>	<b>\$ (126.3)</b>	<b>\$ (382.7)</b>	<b>\$ (110.2)</b>

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

<b>Merial</b>	4Q `06	4Q `05	YTD 2006	YTD 2005
IVOMEK, HEARTGARD, other avermectins	\$ 106.7	\$ 117.3	\$ 468.7	\$ 467.5
FRONTLINE	154.3	144.0	886.9	757.7
Biologicals	165.1	149.0	600.7	533.2
Other Animal Health	63.0	57.0	238.4	229.1
<b>TOTAL MERIAL SALES</b>	<b>\$ 489.1</b>	<b>\$ 467.3</b>	<b>\$ 2,194.7</b>	<b>\$ 1,987.5</b>

<b>Sanofi Pasteur-MSD</b>	4Q `06	4Q `05	YTD 2006	YTD 2005
HEPATITIS VACCINES	\$ 16.6	\$ 15.0	\$ 70.9	\$ 81.0
VIRAL VACCINES	30.5	17.6	100.1	78.5
Other Vaccines	287.3	166.0	742.9	705.0
<b>TOTAL SANOFI-MSD SALES</b>	<b>\$ 334.4</b>	<b>\$ 198.6</b>	<b>\$ 913.9</b>	<b>\$ 864.5</b>

<b>Merck / Schering-Plough Collaboration</b>	4Q `06	4Q `05	YTD 2006	YTD 2005
VYTORIN (Worldwide)	\$ 552.9	\$ 354.9	\$ 1,955.3	\$ 1,028.3
ZETIA (Worldwide)	536.1	391.4	1,928.8	1,396.7
<b>TOTAL</b>	<b>\$ 1,089.0</b>	<b>\$ 746.3</b>	<b>\$ 3,884.1</b>	<b>\$ 2,425.0</b>